Aliases & Classifications for Lens Disease

Summaries for Lens Disease

MalaCards based summary : Lens Disease, also known as lens diseases, is related to cataract and traumatic glaucoma, and has symptoms including eye manifestations An important gene associated with Lens Disease is CRYAA (Crystallin Alpha A). The drugs Estradiol and Ethinyl Estradiol have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and testes, and related phenotype is vision/eye.

Related Diseases for Lens Disease

Diseases related to Lens Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 42)
# Related Disease Score Top Affiliating Genes
1 cataract 27.7 AKR1B1 CRYAA CRYAB CRYBB2 CRYGA CRYGS
2 traumatic glaucoma 10.6 OPTN PHEX
3 chronic closed-angle glaucoma 10.5 OPTN PHEX
4 morning glory syndrome 10.5 GJA3 PAX6
5 acute closed-angle glaucoma 10.5 OPTN PEX19
6 morgagni cataract 10.5 CRYAA PHEX
7 scleral staphyloma 10.5 OPTN PAX6
8 nuclear senile cataract 10.4 CRYAA CRYGS LAMA3
9 glaucoma 3, primary congenital, a 10.4 CRYGS OPTN PAX6
10 juvenile glaucoma 10.4 OPTN PAX6 PHEX
11 degenerative myopia 10.4 CRYAA VEGFA
12 cataract 30, multiple types 10.4 CRYBB2 GJA3
13 diabetic cataract 10.3 AKR1B1 GBA3 VEGFA
14 vitreous detachment 10.3 LAMA3 VEGFA
15 eye accommodation disease 10.3 CRYAA CRYGS MIP
16 presbyopia 10.3 CRYAA CRYGS MIP
17 cataract-glaucoma 10.3 OCRL PITX3
18 congenital aphakia 10.3 FOXE3 OPTN PAX6
19 glaucoma, normal tension 10.3 LOXL1 OPTN
20 aniridia 1 10.3 FOXE3 OPTN PAX6
21 yemenite deaf-blind hypopigmentation syndrome 10.3 OPTN VEGFA
22 sclerocornea 10.3 FOXE3 OPTN
23 coloboma of macula 10.3 FOXE3 OPTN PAX6
24 blood group, globoside system 10.3 CRYAA CRYGS OPTN VEGFA
25 cataract microcornea syndrome 10.3 CRYAA CRYBB2
26 cataract 25 10.2 CRYBB2 CRYGS MIP
27 cataract 44 10.2 CRYAA CRYBB2 MIP
28 cerulean cataract 10.2 CRYBB2 MIP
29 posterior polar cataract 10.2 CRYAB GJA3 PITX3
30 anterior segment dysgenesis 2 10.2 FOXE3 PITX3
31 cataract 9, multiple types 10.2 CRYAA CRYBB2
32 intraocular pressure quantitative trait locus 10.2 LOXL1 OPTN
33 glaucoma, primary open angle 10.2 LOXL1 OPTN PHEX
34 mature cataract 10.1 CRYAA CRYBB2 CRYGS MIP
35 peters-plus syndrome 10.1 FOXE3 PAX6 PITX3
36 neovascular glaucoma 10.0 OPTN VEGFA
37 anterior segment dysgenesis 1 10.0 CRYGS FOXE3 PAX6 PITX3
38 phacogenic glaucoma 9.9 CRYAA LOXL1 OPTN PEX19 PHEX
39 early-onset nuclear cataract 9.9 CRYAA CRYAB CRYBB2 GJA3 MIP
40 iris disease 9.8 CRYAA LOXL1 OPTN PAX6 PEX19 PHEX
41 cataract 16, multiple types 9.6 CRYAA CRYAB CRYGS GJA3 MIP PITX3
42 branchiootic syndrome 1 9.5

Graphical network of the top 20 diseases related to Lens Disease:



Diseases related to Lens Disease

Symptoms & Phenotypes for Lens Disease

UMLS symptoms related to Lens Disease:


eye manifestations

MGI Mouse Phenotypes related to Lens Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.4 AKR1B1 CRYAB CRYBB2 CRYGA CRYGS GJA3

Drugs & Therapeutics for Lens Disease

Drugs for Lens Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 287)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-28-2 5757
2
Ethinyl Estradiol Approved Phase 4,Phase 2,Phase 3,Phase 1 57-63-6 5991
3
Moxifloxacin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 151096-09-2, 354812-41-2 152946
4
Norgestimate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 35189-28-7 6540478
5
Dipivefrin Approved Phase 4,Phase 3 52365-63-6 3105
6
Loteprednol Approved Phase 4,Phase 3 129260-79-3, 82034-46-6 9865442 444025
7
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
8
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
9
Ketorolac Approved Phase 4,Phase 3 74103-06-3, 66635-83-4 3826
10
Nepafenac Approved, Investigational Phase 4,Phase 3,Phase 2 78281-72-8 151075
11
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 1 9004-61-9 53477741 24759
12
Gabapentin Approved, Investigational Phase 4,Phase 1,Phase 2 60142-96-3 3446
13
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 1,Phase 2 56-12-2 119
14
Lidocaine Approved, Vet_approved Phase 4,Phase 1 137-58-6 3676
15
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-02-2 5743
16
Ephedrine Approved Phase 4,Phase 3,Phase 2 299-42-3 9294
17
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2 90-82-4 7028
18
Heparin Approved, Investigational Phase 4,Phase 2 9005-49-6 46507594 772
19
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
20
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
21
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
22
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 124-94-7 31307
23
Vancomycin Approved Phase 4,Phase 3 1404-90-6 14969 441141
24
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
25 Racepinephrine Approved Phase 4 329-65-7
26
Dinoprostone Approved Phase 4 363-24-6 5280360
27
Levofloxacin Approved, Investigational Phase 4,Phase 3 100986-85-4 149096
28
Ofloxacin Approved Phase 4,Phase 3 82419-36-1 4583
29
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 76631-46-4, 113775-47-6 5311068 56032 68602
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
31
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
32
Azithromycin Approved Phase 4 83905-01-5 53477736 447043 55185
33
Gatifloxacin Approved, Investigational Phase 4,Phase 1 112811-59-3 5379
34
Ciprofloxacin Approved, Investigational Phase 4,Phase 1,Phase 2 85721-33-1 2764
35
Bimatoprost Approved, Investigational Phase 4,Phase 2 155206-00-1 5311027
36
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
37
Dalteparin Approved Phase 4 9005-49-6
38
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
39
Difluprednate Approved Phase 4,Phase 3 23674-86-4 443936
40
Brinzolamide Approved Phase 4 138890-62-7 68844
41
Tobramycin Approved, Investigational Phase 4,Phase 3,Phase 2 32986-56-4 36294 5496
42
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
43 Homatropine Approved Phase 4 87-00-3
44
Oxymetazoline Approved, Investigational Phase 4,Phase 3 1491-59-4 4636
45
Phenylephrine Approved Phase 4,Phase 3 59-42-7 6041
46
Remifentanil Approved Phase 4 132875-61-7 60815
47
Theobromine Approved, Investigational Phase 4 83-67-0 5429
48 tannic acid Approved, Nutraceutical Phase 4
49 Orange Approved, Nutraceutical Phase 4
50
Bromfenac Approved July 1997 Phase 4,Phase 3,Phase 2,Phase 1 91714-94-2 60726

Interventional clinical trials:

(show top 50) (show all 740)

# Name Status NCT ID Phase Drugs
1 Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens Unknown status NCT02378636 Phase 4
2 Clinical Investigation of the Bi Flex M Multifocal IOL Unknown status NCT02338882 Phase 4
3 A Intra-patient Comparison of Closed Loop and Plate Haptic Toric Intraocular Lenses Unknown status NCT02264457 Phase 4
4 Tear Film Evaluation After Phacoemulsification Unknown status NCT02238015 Phase 4
5 Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular Lens Unknown status NCT01615861 Phase 4
6 Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery Unknown status NCT01382641 Phase 4
7 A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery Unknown status NCT01296542 Phase 4
8 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Unknown status NCT01296191 Phase 4 Moxifloxacin;besifloxacin
9 AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL Unknown status NCT01278420 Phase 4
10 Efficacy of Subtenon's Block With Olive Tipped Cannula Unknown status NCT01019018 Phase 4
11 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4 Pred Forte;Lotemax
12 Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies Unknown status NCT00865540 Phase 4 prednisolone acetate 1%;ketorolac tromethamine 0.4%;nepafenac 0.1%;methylcellulose 0.5%
13 Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery Unknown status NCT01455467 Phase 4
14 A Study of the iStent in Combo With Cataract Surgery in Newly Diagnosed Open Angle Glaucoma or OH Patients. Unknown status NCT00326066 Phase 4
15 Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial Unknown status NCT00273221 Phase 4
16 Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia Unknown status NCT01554761 Phase 4
17 Effect of Gabapentin on Pain of the Second Cataract Surgery Unknown status NCT02127853 Phase 4 gabapentin;placebo
18 Spherical Aberration and Contrast Sensitivity in IOLs Completed NCT00576485 Phase 4
19 Sedation Methods During Cataract Surgery Completed NCT03054103 Phase 4 Midazolam + Ketamine 10 MG/ML: 0.5 ML;Midazolam + Ketamine 10 MG/ML: 1 ML;Midazolam + Normal saline
20 Patient-controlled Sedation With Propofol During Cataract Surgery Under Topical Anesthesia Completed NCT02771912 Phase 4 Propofol;Placebo
21 Clinical Outcomes After Bilateral Implantation of ZEISS AT LISA TRI AND TRI TORIC IOL Completed NCT02770924 Phase 4
22 Visual Acuity After the Combined Binocular Implantation of +2.0 Diopters and +3.0 Diopters Oculentis Multifocal Intraocular Lenses. Completed NCT02633228 Phase 4
23 Visual Acuity After the Combined Binocular Implantation of +2.75 Diopters and +3.25 Diopters Tecnis Multifocal Intraocular Lenses. Completed NCT02633072 Phase 4
24 Dropless vs. Standard Drops Contralateral Eye Study Completed NCT02515045 Phase 4 TriMoxiVanc;Moxifloxacin HCl 0.5%;Ilevro;Prednisolone acetate 1%
25 Visual Acuity After the Combined Binocular Implantation of +2.5 Diopters and +3.0 Diopters ReSTOR Multifocal Intraocular Lenses. Completed NCT02314572 Phase 4
26 A Comparison of One-site and Two-site Peribulbar Anaesthesia for Cataract Surgery at Kaduna, Nigeria Completed NCT02150460 Phase 4
27 Parameters of 2 Phaco Tips Designs in Torsional Phacoemulsification Completed NCT02089698 Phase 4
28 Long-term (3 Months) Safety of Femtosecond-laser Assisted Cataract Surgery Completed NCT02023437 Phase 4
29 Addressing of Efficacy and Safety of Femtosecond-laser Assisted Versus Manual Lens Fragmentation Procedure Completed NCT01971177 Phase 4
30 Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients Completed NCT01859702 Phase 4 Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution
31 A Single Centre Study to Analyze Cataract Surgery Following Femtosecond Laser-Assisted and Manual Cataract Surgery Completed NCT01769313 Phase 4
32 Time Study for Biometry Measurements With the Lenstar and IntraOcularLens (IOL) Master 500 Completed NCT01550939 Phase 4
33 Visual Outcomes After Implantation of a New Multifocal Intraocular Lens Completed NCT01505816 Phase 4
34 2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery Completed NCT01455233 Phase 4 besivance;vigamox
35 Laser Cataract Surgery With the Femtosecond Laser Technology Completed NCT01382823 Phase 4
36 Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions Completed NCT01298973 Phase 4 Viscoat;Saline
37 Comparison of Postoperative Visual Acuity and Spectacle Independence Between the Tecnis Multifocal Intraoculer Lens (IOL) and the Crystalens Accommodating IOL Completed NCT01275118 Phase 4
38 Evaluation of Effective Lens Position With a Uniplanar Bi-aspheric IOL Completed NCT01248572 Phase 4
39 Visual Performance of Bilateral AcrySof ReSTOR Aspheric +4 Completed NCT01215045 Phase 4
40 Clinical Evaluation of the One-Piece Tecnis Multifocal Intraocular Lens (IOL) Completed NCT01210807 Phase 4
41 Efficacy Evaluation of SYSTANE® ULTRA in Patients Scheduled for Cataract Surgery Completed NCT01199510 Phase 4
42 Evaluation of 3 Intraocular Lenses Following Lens Extraction Completed NCT01122576 Phase 4
43 Evaluation Of Bilateral Tecnis Multifocal Versus ReSTOR 3D Intraocular Lenses Completed NCT01061918 Phase 4
44 Evaluation of the Tecnis™ Multifocal and Crystalens™ Accommodating Intraocular Lenses Completed NCT01061281 Phase 4
45 Spherical Aberration and Contrast Sensitivity Function in Eyes Implanted With Spherical and Aspheric Intraocular Lenses: A Clinical Trial Completed NCT01028872 Phase 4
46 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification Completed NCT01021761 Phase 4 Ketorolac Tromethamine;Bromfenac;nepafenac
47 Outcomes of Phacoemulsification With Torsional Ultrasound Completed NCT01010490 Phase 4
48 A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification Completed NCT01001806 Phase 4 Ketorolac Tromethamine 0.45%;bromfenac 0.09%;nepafenac 0.1%
49 Selection of Aspheric Diffractive Multifocal Intraocular Lens (IOLS) Based on Corneal Wavefront Completed NCT00999492 Phase 4
50 Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric IOL Completed NCT00934622 Phase 4

Search NIH Clinical Center for Lens Disease

Cochrane evidence based reviews: lens diseases

Genetic Tests for Lens Disease

Anatomical Context for Lens Disease

MalaCards organs/tissues related to Lens Disease:

38
Eye, Endothelial, Testes, Bone, Prostate

Publications for Lens Disease

Articles related to Lens Disease:

# Title Authors Year
1
Concomitant progressive deafness, chronic nephritis, and ocular lens disease. ( 13950238 )
1963

Variations for Lens Disease

Expression for Lens Disease

Search GEO for disease gene expression data for Lens Disease.

Pathways for Lens Disease

GO Terms for Lens Disease

Biological processes related to Lens Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.83 AKR1B1 CRYAA CRYAB FOXE3 VEGFA
2 protein stabilization GO:0050821 9.62 CRYAA CRYAB GBA3 PEX19
3 dopaminergic neuron differentiation GO:0071542 9.52 PITX3 VEGFA
4 positive regulation of neuroblast proliferation GO:0002052 9.51 PAX6 VEGFA
5 negative regulation of neurogenesis GO:0050768 9.49 PAX6 PITX3
6 eye photoreceptor cell development GO:0042462 9.48 PAX6 VEGFA
7 monocyte differentiation GO:0030224 9.46 MYH9 VEGFA
8 camera-type eye development GO:0043010 9.46 CRYAB CRYBB2 FOXE3 PAX6
9 visual perception GO:0007601 9.43 CRYAA CRYBB2 CRYGA GJA3 MIP PAX6
10 iris morphogenesis GO:0061072 9.4 FOXE3 PAX6
11 cornea development in camera-type eye GO:0061303 9.37 FOXE3 PAX6
12 negative regulation of intracellular transport GO:0032387 9.26 CRYAA CRYAB
13 lens development in camera-type eye GO:0002088 9.17 CRYAB CRYGA CRYGS FOXE3 MIP PAX6

Molecular functions related to Lens Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of eye lens GO:0005212 9.1 CRYAA CRYAB CRYBB2 CRYGA CRYGS MIP

Sources for Lens Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....